284 related articles for article (PubMed ID: 5014617)
1. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin.
Merskey C; Johnson AJ; Lalezari P
J Clin Invest; 1972 Apr; 51(4):903-11. PubMed ID: 5014617
[TBL] [Abstract][Full Text] [Related]
2. Fibrin lysis by thrombin elevating levels of fibrinogen and fibrin-related antigen (FR-antigen) in human serum as shown by Auto Analyzer assay.
Merskey C; Johnson AJ; Lalezari P
J Clin Pathol; 1972 Jul; 25(7):623. PubMed ID: 5070262
[No Abstract] [Full Text] [Related]
3. Tanned Red Cell Hemagglutination Inhibition Immunoassay for fibrinogen-fibrin-related antigen ("fibrinolytic degradation products") in human serum.
Merskey C; Lalezari P; Johnson AJ
Scand J Haematol Suppl; 1971; 13():83-5. PubMed ID: 5290706
[No Abstract] [Full Text] [Related]
4. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
Pizzo SV; Schwartz ML; Hill RL; McKee PA
J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
[TBL] [Abstract][Full Text] [Related]
5. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
6. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome.
Gandrille S; Jouvin MH; Toulon P; Remy P; Fiessinger JN; Roncato M; Moatti N; Aiach M
Thromb Haemost; 1988 Jun; 59(3):445-50. PubMed ID: 3142081
[TBL] [Abstract][Full Text] [Related]
7. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
Jacobsen CD; Fry GL; Wu KK; Southers NJ
Thromb Res; 1975 Apr; 6(4):327-36. PubMed ID: 1079637
[No Abstract] [Full Text] [Related]
9. The inactivation of hemostatic factors by hematin.
Green D; Reynolds N; Klein J; Kohl H; Ts'ao CH
J Lab Clin Med; 1983 Sep; 102(3):361-9. PubMed ID: 6411843
[TBL] [Abstract][Full Text] [Related]
10. Isolation of fibrinogen-fibrin related antigen from human plasma by immuno-affinity chromatography: its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer.
Merskey C; Johnson AJ; Harris JU; Wang MT; Swain S
Br J Haematol; 1980 Apr; 44(4):655-70. PubMed ID: 7378321
[TBL] [Abstract][Full Text] [Related]
11. The enhanced activation of Glu-plasminogen by urokinase in the presence of fibrin or des A fibrin as measured by the release of B beta peptide and FDP.
Urano T; Takada Y; Takada A
Thromb Res; 1984 Dec; 36(5):429-35. PubMed ID: 6084324
[TBL] [Abstract][Full Text] [Related]
12. Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.
Harris JU; Johnson AJ; Merskey C; Wang MT; Robinson D
Biochem J; 1979 Dec; 183(3):623-32. PubMed ID: 540036
[TBL] [Abstract][Full Text] [Related]
13. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease.
Kim PY; Stewart RJ; Lipson SM; Nesheim ME
J Thromb Haemost; 2007 Jun; 5(6):1250-6. PubMed ID: 17266698
[TBL] [Abstract][Full Text] [Related]
14. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
Lenfors S; Gustafsson D
Semin Thromb Hemost; 1996; 22(4):335-42. PubMed ID: 8944418
[TBL] [Abstract][Full Text] [Related]
15. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light.
Suontaka AM; Blombäck M; Chapman J
Transfusion; 2003 May; 43(5):568-75. PubMed ID: 12702176
[TBL] [Abstract][Full Text] [Related]
16. New method to prepare autologous fibrin glue on demand.
Alston SM; Solen KA; Broderick AH; Sukavaneshvar S; Mohammad SF
Transl Res; 2007 Apr; 149(4):187-95. PubMed ID: 17383592
[TBL] [Abstract][Full Text] [Related]
17. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
[TBL] [Abstract][Full Text] [Related]
19. [A simple method for the determination of intravascular clotting and fibrinolysis].
Latallo ZS; Wegrzynowicz Z; Kopeć M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1972; 97(1):32-5. PubMed ID: 4114580
[No Abstract] [Full Text] [Related]
20. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
